Fate Therapeutics (NASDAQ: FATE) reported Q3 EPS of ($0.86), $0.03 better than the analyst estimate of ($0.89). Revenue for the quarter came in at $14.98 million versus the consensus estimate of $15.71 million.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.